Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

被引：12

作者：

Collier, Anderson B., III ^{[1
]}

Krailo, Mark D. ^{[2
]}

Dang, Ha M. ^{[2
]}

DuBois, Steven G. ^{[3
,4
]}

Hawkins, Douglas S. ^{[5
]}

Bernstein, Mark L. ^{[6
]}

Bomgaars, Lisa R. ^{[7
]}

Reed, Damon R. ^{[8
,9
,10
]}

Gorlick, Richard G. ^{[11
]}

Janeway, Katherine A. ^{[3
,4
]}

机构：

[1] Univ Mississippi, Dept Pediat, Med Ctr, 2500 North Sate St, Jackson, MS 38219 USA

[2] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA

[3] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

[4] Harvard Med Sch, Boston, MA 02115 USA

[5] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA

[6] Dalhousie Univ, IWK Hlth Ctr, Port Williams, NS, Canada

[7] Baylor Coll Med, Dept Pediat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

[8] Johns Hopkins All Childrens Hosp, Canc Ctr, St Petersburg, FL USA

[9] Johns Hopkins All Childrens Hosp, Blood Disorders Inst, St Petersburg, FL USA

[10] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 12期

关键词：

event-free survival; Ewing sarcoma; objective response; outcome; phase; 2; trials; relapsed; REFRACTORY SOLID TUMORS; II TRIAL; CHEMOTHERAPY; CRITERIA;

D O I：

10.1002/pbc.29333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

引用

页数：5

共 50 条

[21] Imaging guidelines for children with Ewing sarcoma and osteosarcoma: A report from the Children's Oncology Group Bone Tumor Committee
Meyer, James S.
Nadel, Helen R.
Marina, Neyssa
Womer, Richard B.
Brown, Kenneth L. B.
Eary, J. F.
Gorlick, Richard
Grier, Holcombe E.
Randall, R. Lor
Lawlor, Elizabeth R.
Lessnick, Stephen L.
Schomberg, Paula J.
Kailo, Mark D.
PEDIATRIC BLOOD & CANCER, 2008, 51 (02) : 163 - 170
[22] Evaluation of local control in patients with non-metastatic Ewing sarcoma of the bone: A report from the Children's Oncology Group
DuBois, S. G.
Krailo, M. D.
Cook, E. F.
Tarbell, N. J.
Fryer, C. J.
Gebhardt, M. C.
Brown, K.
Miser, J. S.
Marina, N. M.
Grier, H. E.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[23] Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children's Oncology Group.
DuBois, Steven G.
Krailo, Mark D.
Gebhardt, Mark C.
Donaldson, Sarah S.
Marcus, Karen Chayt
Dormans, John P.
Shamberger, Robert C.
Sailer, Scott Lee
Nicholas, Richard W.
Healey, John H.
Tarbell, Nancy
Devidas, Meenakshi
Meyer, James S.
Granowetter, Linda
Womer, Richard
Bernstein, Mark L.
Marina, Neyssa
Grier, Holcombe E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[24] Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children's Oncology Group
Shukla, Neerav
Schiffman, Joshua D.
Reed, Damon
Davis, Ian J.
Womer, Richard B.
Lessnick, Stephen L.
Lawlor, Elizabeth R.
FRONTIERS IN ONCOLOGY, 2013, 3
[25] Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group
Aye, Jamie M.
Xue, Wei
Palmer, Joshua D.
Walterhouse, David O.
Arnold, Michael A.
Heaton, Todd E.
Venkatramani, Rajkumar
PEDIATRIC BLOOD & CANCER, 2021, 68 (04)
[26] Response to "Imaging Guidelines for Children With Ewing Sarcoma and Osteosarcoma: A Report From the Children's Oncology Group Bone Tumor Committee"
Meyer, James S.
Nadel, Helen R.
Marina, Neyssa
Womer, Richard B.
Brown, Kenneth L. B.
Eary, J. F.
Gorlick, Richard
Grier, Holcombe E.
Randall, R. Lor
Lawlor, Elizabeth R.
Lessnick, Stephen L.
Schomberg, Paula J.
Kailo, Mark D.
PEDIATRIC BLOOD & CANCER, 2008, 51 (06) : 839 - 840
[27] Clinical Outcome of Patients with Recurrent/Refractory Localized Ewing's Sarcoma Family of Tumors: A Retrospective Report From the JESS Group
Umeda, Katsutsugu
Miyamura, Takako
Yamada, Kenji
Hosono, Ako
Sano, Hideki
Sumi, Minako
Okita, Hajime
Hosoya, Yosuke
Chin, Motoaki
Ozaki, Toshifumi
PEDIATRIC BLOOD & CANCER, 2020, 67
[28] Molecular characterization of patients with localized Ewing sarcoma targeting discrete prognostic groups: A report from the Children's Oncology Group.
Gillani, Riaz
Shulman, David Stephen
Klega, Kelly S.
DelRocco, Natalie J.
Krailo, Mark D.
Han, Ruxu
Slack, Jonathan
Bainer, Victoria
Armstrong, Jessica
Church, Alanna J.
Crompton, Brian D.
Janeway, Katherine A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group
Malempati, Suman
Weigel, Brenda
Ingle, Ashish M.
Ahern, Charlotte H.
Carroll, Julie M.
Roberts, Charles T.
Reid, Joel M.
Schmechel, Stephen
Voss, Stephan D.
Cho, Steven Y.
Chen, Helen X.
Krailo, Mark D.
Adamson, Peter C.
Blaney, Susan M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (03) : 256 - 262
[30] Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group
Bernstein, ML
Devidas, M
Lafreniere, D
Souid, AK
Meyers, PA
Gebhardt, M
Stine, K
Nicholas, R
Perlman, EJ
Dubowy, R
Wainer, IW
Dickman, PS
Link, MP
Goorin, A
Grier, HE
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 152 - 159

← 1 2 3 4 5 →